Elucidation of CYP2D6 genetic diversity in a unique African population: Implications for the future application of pharmacogenetics in the xhosa population

Annals of Human Genetics

Volumn 74, Issue 4, 2010, Pages 340-350

  Wright, Galen E B ^a   Niehaus, Dana J H ^a   Drögemöller, Britt I ^a   Koen, Liezl ^a   Gaedigk, Andrea ^b   Warnich, Louise ^a  

^a STELLENBOSCH UNIVERSITY   (South Africa)

^b CHILDREN S MERCY HOSPITAL   (United States)

Author keywords

CYP2D6; Pharmacogenetics; Schizophrenia; South African population; Xhosa

Indexed keywords

ANTIDEPRESSANT AGENT; CYTOCHROME P450 2D6; DRUG METABOLIZING ENZYME; GENOMIC DNA; NEUROLEPTIC AGENT; PRIMER DNA;

ALLELE; ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; ENZYME ACTIVITY; ENZYME METABOLISM; GENE IDENTIFICATION; GENE LOCUS; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MENTAL PATIENT; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; POPULATION RESEARCH; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; SCHIZOPHRENIA; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SOUTH AFRICA;

AFRICAN CONTINENTAL ANCESTRY GROUP; CYTOCHROME P-450 CYP2D6; GENETIC VARIATION; GENOTYPE; HUMANS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; SCHIZOPHRENIA; SOUTH AFRICA;

EID: 77954765466     PISSN: 00034800     EISSN: 14691809     Source Type: Journal    
DOI: 10.1111/j.1469-1809.2010.00585.x     Document Type: Article

References (38)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. 1994, Washington, DC, APA
2. Arranz M J, de Leon J. Pharmacogenetics and pharmacogenomics of schizophrenia: a review of the last decade of research. Mol Psychiatry 2007, 12:707-747.
3. Barrett J C, Fry B, Maller J, Daly M J. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005, 21:263-265.
4. Brunak S, Engelbrecht J, Knudsen S. Prediction of human mRNA donor and acceptor sites from the DNA sequence. J Mol Biol 1991, 220:49-65.
5. de Leon J, Susce M T, Johnson M, Hardin M, Maw L, Shao A, Allen A C, Chiafari F A, Hillman G, Nikoloff D M. DNA microarray technology in the clinical environment: the AmpliChip CYP450 test for CYP2D6 and CYP2C19 genotyping. CNS Spectr 2009, 14:19-34.
6. Dorado P, Peñas-LLedó E M, LLerena A. CYP2D6 polymorphism: implications for antipsychotic drug response, schizophrenia and personality traits. Pharmacogenomics 2007, 8:1597-1608.
7. Fleeman N, McLeod C, Bagust A, Beale S, Boland A, Dundar Y, Jorgensen A, Payne K, Pirmohamed M, Pushpakom S, Walley T, de Warren-Penny P, Dickson R. The clinical effectiveness and cost-effectiveness of testing for cytochrome P450 polymorphisms in patients with schizophrenia treated with antipsychotics: a systematic review and economic evaluation. Health Technol Assess 2010, 14:1-157.
8. Gaedigk A, Bhathena A, Ndjountché L, Pearce R E, Abdel-Rahman S M, Alander S W, Bradford L D, Leeder J S. Identification and characterization of novel sequence variations in the cytochrome P4502D6 (CYP2D6) gene in African Americans. Pharmacogenomics J 2005, 5:173-182.
9. Gaedigk A, Ndjountché L, Divakaran K, Bradford L D, Zineh I, Oberlander T F, Brousseau D C, McCarver D G, Johnson J A, Alander S W, Riggs W K, Leeder J S. Cytochrome P4502D6 (CYP2D6) gene locus heterogeneity: characterization of gene duplication events. Clin Pharmacol Ther 2007, 81:242-251.
10. Gaedigk A, Coetsee C. The CYP2D6 gene locus in South African Coloureds: unique allele distributions, novel alleles and gene arrangements. Eur J Clin Pharmacol 2008, 64:465-475.
11. Gaedigk A, Simon S D, Pearce R E, Bradford L D, Kennedy M J, Leeder J S. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther 2008, 83:234-242.
12. Jakobsson M, Scholz S W, Scheet P, Gibbs J P, VanLiere J M, Fung H-C, Szpiech Z A, Degnan J H, Wang K, Guerreiro R, Bras J M, Schymick J C, Hernandez D G, Traynor B J, Simon-Sanchez J, Matarin M, Britton A, van de Leemput J, Rafferty I, Bucan M, Cann H M, Hardy J A, Rosenberg N A, Singleton A B. Genotype, haplotype and copy-number variation in worldwide human populations. Nature 2008, 45:998-1003.
13. Kirchheiner J, Nickchen K, Bauer M, Wong M-L, Licinio J, Roots I, Brockmöller J. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry 2004, 9:442-472.
14. Kobylecki C J, Jakobsen K D, Hansen T, Jakobsen I V, Rasmussen H B, Werge T. CYP2D6 genotype predicts antipsychotic side effects in schizophrenia inpatients: a retrospective matched case-control study. Neuropsychobiology 2009, 59:222-226.
15. Koen L, Magni P, Niehaus D J, Le Roux A. Antipsychotic prescription patterns in Xhosa patients with schizophrenia or schizoaffective disorder. Afr J Psychiatry 2008, 11:287-290.
16. Lane A B, Soodyall H, Arndt S, Ratshikhopha M E, Jonker E, Freeman C, Young L, Morar B, Toffie L. Genetic substructure in South African Bantu-speakers: evidence from autosomal DNA and Y-chromosome studies. Am J Phys Anthropol 2002, 119:175-185.
17. Lieberman J A, Stroup T S, McEvoy J P, Swartz M S, Rosenheck R A, Perkins D O, Keefe R S, Davis S M, Davis C E, Lebowitz B D, Severe J, Hsiao J K. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005, 353:1209-1223.
18. Løvlie R, Daly A K, Matre G E, Molven A, Steen V M. Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype: a role for the CYP2D6*35 allele in ultrarapid metabolism?. Pharmacogenetics 2001, 11:45-55.
19. Masimirembwa C, Persson I, Bertilsson L, Hasler J, Ingelman-Sundberg M. A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: association with diminished debrisoquine hydroxylase activity. Br J Clin Pharmacol 1996, 42:713-719.
20. Matimba A, Del-Favero J, Van Broeckhoven C, Masimirembwa C. Novel variants of major drug-metabolising enzyme genes in diverse African populations and their predicted functional effects. Hum Genomics 2009, 3:169-190.
21. Mehta U, Durrheim D N, Blockman M, Kredo T, Gounden R, Barnes K I. Adverse drug reactions in adult medical inpatients in a South African hospital serving a community with a high HIV/AIDS prevalence: prospective observational study. Br J Clin Pharmacol 2008, 65:396-406.
22. Miller S A, Dykes D D, Polesky H F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988, 16:1215.
23. Miller M. Tools for population genetic analyses (TFGA) 1.3: a Windows program for the analysis of allozyme and molecular population genetic data. 1997, Computer software distributed by the author
24. Ng P C, Henikoff S. SIFT: predicting amino acid changes that affect protein function. Nucleic Acids Res 2003, 31:3812-3814.
25. Nurse G T, Weiner J S, Jenkins T. The Khoi as migrants and nomads. The peoples of Southern Africa and their Affinities 1985, p81-83. Harrison G A, Oxford, Clarendon Press
26. Oscarson M, Hidestrand M, Johansson I, Ingelman-Sundberg M. A combination of mutations in the CYP2D6*17 (CYP2D6Z) allele causes alterations in enzyme function. Mol Pharmacol 1997, 52:1034-1040.
27. Ragia G, Arvanitidis K I, Tavridou A, Manolopoulos V G. Need for reassessment of reported CYP2C19 allele frequencies in various populations in view of CYP2C19*17 discovery: the case of Greece. Pharmacogenomics 2009, 10:43-49.
28. Raimundo S, Fischer J, Eichelbaum M, Griese E-U, Schwab M, Zanger U M. Elucidation of the genetic basis of the common 'intermediate metabolizer' phenotype for drug oxidation by CYP2D6. Pharmacogenetics 2000, 10:577-581.
29. Ramensky V, Bork P, Sunyaev S. Human non-synonymous SNPs: server and survey. Nucleic Acids Res 2002, 30:3894-3900.
30. Seedat S, Emsley R A, Stein D J. Land of promise: challenges and opportunities for research in South Africa. Mol Psychiatry 2004, 9:891-892.
31. Sistonen J, Fuselli S, Levo A, Sajantila A. CYP2D6 genotyping by a multiplex primer extension reaction. Clin Chem 2005, 51:1291-1295.
32. Sistonen J, Sajantila A, Lao O, Corander J, Barbujani G, Fuselli S. CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenet Genomics 2007, 17:93-101.
33. Solus J F, Arietta B J, Harris J R, Sexton D P, Steward J Q, McMunn C, Ihrie P, Mehall J M, Edwards T L, Dawson E P. Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population. Pharmacogenomics 2004, 5:895-931.
34. Steen V M, Andreassen O A, Daly A K, Tefre T, Børresen A L, Idle J R, Gulbrandsen A K. Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology. Pharmacogenetics 1995, 5:215-223.
35. Steimer W, Zöpf K, von Amelunxen S, Pfeiffer H, Bachofer J, Popp J, Messner B, Kissling W, Leucht S. Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers. Clin Chem 2004, 50:1623-1633.
36. Wennerholm A, Johansson I, Hidestrand M, Bertilsson L, Gustafsson L L, Ingelman-Sundberg M. Characterization of the CYP2D6*29 allele commonly present in a black Tanzanian population causing reduced catalytic activity. Pharmacogenetics 2001, 11:417-427.
37. Yu N, Chen F C, Ota S, Jorde L B, Pamilo P, Patthy L, Ramsay M, Jenkins T, Shyue S K, Li W H. Larger genetic differences within Africans than between Africans and Eurasians. Genetics 2002, 161:269-274.
38. Zanger U M, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn-Schmiedeberg's Arch Pharmacol 2004, 369:23-37.